Bosentan
- Generic Name
- Bosentan
- Brand Names
- Stayveer, Tracleer
- Drug Type
- Small Molecule
- Chemical Formula
- C27H29N5O6S
- CAS Number
- 147536-97-8
- Unique Ingredient Identifier
- XUL93R30K2
- Background
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
- Indication
Used in the treatment of pulmonary arterial hypertension (PAH), to improve exercise ability and to decrease the rate of clinical worsening (in patients with WHO Class III or IV symptoms).
- Associated Conditions
- NYHA Functional Class II-IV Pulmonary arterial hypertension, Ocular Inflammation, Ocular bacterial infections
- Associated Therapies
- -
Actelion Pharmaceuticals Ltd.
Actelion Pharmaceuticals Ltd., a Swiss biopharmaceutical company founded in 1997, specializes in drugs for rare diseases, notably pulmonary arterial hypertension (PAH). Acquired by Johnson & Johnson in 2017 for $30 billion, it spun off its R&D unit into Idorsia. Actelion faced legal issues over drug pricing and kickbacks, settling for $360 million. It collaborates with Analytics 4 Life to improve pulmonary hypertension diagnosis.
Drug discovery hotspots: What is the secret to Switzerland's success
Switzerland excels in life sciences due to its strong regional hubs like Basel, Zurich, and Geneva/Lausanne, fostering innovation through bioparks and collaboration between academia and industry. This ecosystem supports start-ups and attracts global talent, maintaining Switzerland's leadership in drug discovery and biotech advancements.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath